Oric Pharmaceuticals IncNASDAQ:ORIC
- LAST PRICE7.0700
- TODAY'S CHANGE (%)0.1600 (2.3155%)
- Bid / Lots7.0500/ 30
- Ask / Lots7.6200/ 1
- Open / Previous Close6.9700 / 6.9100
- Day Range
- 52 Week Range
- Volume3,877,951
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ORIC |
|---|---|---|
| 09:32 ET | 6461 | 6.91 |
| 09:39 ET | 400 | 7.04 |
| 09:41 ET | 1100 | 6.99 |
| 09:43 ET | 1525 | 7.01 |
| 09:48 ET | 100 | 7.01 |
| 09:50 ET | 1091 | 6.98 |
| 09:52 ET | 1428 | 6.97 |
| 09:59 ET | 1035 | 6.95 |
| 10:06 ET | 1428 | 6.982 |
| 10:08 ET | 571 | 6.96 |
| 10:10 ET | 100 | 6.97 |
| 10:14 ET | 187 | 6.96 |
| 10:17 ET | 300 | 7.015 |
| 10:19 ET | 827 | 6.975 |
| 10:21 ET | 400 | 6.965 |
| 10:24 ET | 400 | 6.94 |
| 10:26 ET | 300 | 6.95 |
| 10:28 ET | 600 | 6.92 |
| 10:30 ET | 400 | 6.92 |
| 10:32 ET | 440 | 6.91 |
| 10:33 ET | 500 | 6.86 |
| 10:35 ET | 300 | 6.85 |
| 10:37 ET | 701 | 6.865 |
| 10:39 ET | 1292 | 6.88 |
| 10:42 ET | 1050 | 6.87 |
| 10:44 ET | 600 | 6.86 |
| 10:46 ET | 260 | 6.87 |
| 10:48 ET | 100 | 6.89 |
| 10:51 ET | 748 | 6.88 |
| 10:53 ET | 100 | 6.86 |
| 10:55 ET | 200 | 6.86 |
| 10:57 ET | 900 | 6.86 |
| 11:00 ET | 400 | 6.86 |
| 11:04 ET | 100 | 6.87 |
| 11:06 ET | 300 | 6.84 |
| 11:08 ET | 300 | 6.845 |
| 11:09 ET | 300 | 6.85 |
| 11:11 ET | 1252 | 6.85 |
| 11:15 ET | 408 | 6.855 |
| 11:18 ET | 400 | 6.84 |
| 11:22 ET | 200 | 6.82 |
| 11:24 ET | 600 | 6.85 |
| 11:26 ET | 200 | 6.845 |
| 11:27 ET | 1664 | 6.86 |
| 11:29 ET | 100 | 6.85 |
| 11:31 ET | 400 | 6.86 |
| 11:33 ET | 600 | 6.86 |
| 11:36 ET | 200 | 6.86 |
| 11:38 ET | 700 | 6.86 |
| 11:40 ET | 552 | 6.84 |
| 11:42 ET | 100 | 6.83 |
| 11:44 ET | 1652 | 6.8299 |
| 11:45 ET | 100 | 6.815 |
| 11:47 ET | 746 | 6.83 |
| 11:49 ET | 200 | 6.82 |
| 11:51 ET | 100 | 6.85 |
| 11:54 ET | 100 | 6.84 |
| 11:56 ET | 200 | 6.87 |
| 11:58 ET | 100 | 6.875 |
| 12:00 ET | 1000 | 6.93 |
| 12:02 ET | 100 | 6.935 |
| 12:03 ET | 100 | 6.92 |
| 12:05 ET | 300 | 6.94 |
| 12:07 ET | 800 | 6.92 |
| 12:09 ET | 958 | 6.9 |
| 12:12 ET | 100 | 6.905 |
| 12:14 ET | 400 | 6.9 |
| 12:18 ET | 1600 | 6.91 |
| 12:20 ET | 406 | 6.89 |
| 12:21 ET | 600 | 6.92 |
| 12:23 ET | 100 | 6.915 |
| 12:25 ET | 300 | 6.935 |
| 12:30 ET | 100 | 6.935 |
| 12:32 ET | 100 | 6.935 |
| 12:34 ET | 2258 | 6.9344 |
| 12:36 ET | 200 | 6.925 |
| 12:38 ET | 700 | 6.89 |
| 12:39 ET | 200 | 6.89 |
| 12:41 ET | 230 | 6.89 |
| 12:43 ET | 1592 | 6.88 |
| 12:45 ET | 200 | 6.88 |
| 12:48 ET | 460 | 6.89 |
| 12:52 ET | 100 | 6.88 |
| 12:54 ET | 1277 | 6.87 |
| 12:56 ET | 300 | 6.88 |
| 12:57 ET | 200 | 6.88 |
| 12:59 ET | 400 | 6.89 |
| 01:01 ET | 413 | 6.85 |
| 01:03 ET | 200 | 6.85 |
| 01:06 ET | 200 | 6.85 |
| 01:08 ET | 400 | 6.88 |
| 01:10 ET | 2423 | 6.87 |
| 01:12 ET | 952 | 6.86 |
| 01:14 ET | 1200 | 6.89 |
| 01:15 ET | 400 | 6.88 |
| 01:17 ET | 100 | 6.88 |
| 01:19 ET | 100 | 6.88 |
| 01:21 ET | 952 | 6.89 |
| 01:24 ET | 859 | 6.87 |
| 01:26 ET | 300 | 6.87 |
| 01:28 ET | 400 | 6.89 |
| 01:30 ET | 1289 | 6.86 |
| 01:32 ET | 1045 | 6.86 |
| 01:33 ET | 443 | 6.86 |
| 01:35 ET | 482 | 6.83 |
| 01:37 ET | 500 | 6.82 |
| 01:39 ET | 1730 | 6.85 |
| 01:42 ET | 3110 | 6.915 |
| 01:44 ET | 968 | 6.9 |
| 01:46 ET | 100 | 6.89 |
| 01:48 ET | 100 | 6.89 |
| 01:50 ET | 200 | 6.89 |
| 01:51 ET | 688 | 6.9 |
| 01:53 ET | 200 | 6.89 |
| 01:55 ET | 200 | 6.88 |
| 01:57 ET | 100 | 6.89 |
| 02:00 ET | 324 | 6.89 |
| 02:02 ET | 1469 | 6.925 |
| 02:04 ET | 323 | 6.91 |
| 02:06 ET | 989 | 6.93 |
| 02:08 ET | 300 | 6.93 |
| 02:09 ET | 800 | 6.92 |
| 02:11 ET | 100 | 6.92 |
| 02:13 ET | 1038 | 6.94 |
| 02:18 ET | 100 | 6.94 |
| 02:20 ET | 900 | 6.975 |
| 02:22 ET | 348 | 6.96 |
| 02:24 ET | 660 | 6.96 |
| 02:26 ET | 100 | 6.96 |
| 02:27 ET | 848 | 6.97 |
| 02:29 ET | 953 | 6.95 |
| 02:31 ET | 200 | 6.94 |
| 02:33 ET | 1440 | 6.94 |
| 02:36 ET | 200 | 6.91 |
| 02:38 ET | 619 | 6.93 |
| 02:40 ET | 1141 | 6.93 |
| 02:42 ET | 100 | 6.92 |
| 02:44 ET | 639 | 6.91 |
| 02:45 ET | 654 | 6.91 |
| 02:47 ET | 100 | 6.91 |
| 02:49 ET | 200 | 6.91 |
| 02:51 ET | 200 | 6.91 |
| 02:54 ET | 885 | 6.9 |
| 02:58 ET | 1287 | 6.91 |
| 03:00 ET | 200 | 6.91 |
| 03:02 ET | 100 | 6.88 |
| 03:03 ET | 997 | 6.88 |
| 03:05 ET | 400 | 6.86 |
| 03:07 ET | 521 | 6.87 |
| 03:09 ET | 600 | 6.87 |
| 03:12 ET | 100 | 6.85 |
| 03:14 ET | 728 | 6.84 |
| 03:16 ET | 600 | 6.86 |
| 03:18 ET | 300 | 6.84 |
| 03:20 ET | 3329 | 6.8625 |
| 03:21 ET | 18788 | 6.88 |
| 03:23 ET | 1100 | 6.87 |
| 03:25 ET | 1532 | 6.875 |
| 03:27 ET | 3039 | 6.89 |
| 03:30 ET | 1221 | 6.89 |
| 03:32 ET | 2650 | 6.89 |
| 03:34 ET | 600 | 6.89 |
| 03:36 ET | 2037 | 6.93 |
| 03:38 ET | 400 | 6.94 |
| 03:39 ET | 500 | 6.94 |
| 03:41 ET | 1100 | 6.93 |
| 03:43 ET | 400 | 6.94 |
| 03:45 ET | 400 | 6.94 |
| 03:48 ET | 1180 | 6.92 |
| 03:50 ET | 5470 | 6.92 |
| 03:52 ET | 23254 | 7.029 |
| 03:54 ET | 3237 | 7.005 |
| 03:56 ET | 13403 | 7.04 |
| 03:57 ET | 10463 | 7.055 |
| 03:59 ET | 20404 | 7.07 |
Jun 7, 2024
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Friday Jun 07, 2024 by Dow Jones
4:30PM ET on Friday Jun 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oric Pharmaceuticals Inc | 476.7M | -3.9x | --- |
Neurogene Inc | 472.4M | -7.9x | --- |
Corbus Pharmaceuticals Holdings Inc | 483.6M | -6.5x | --- |
Altimmune Inc | 471.5M | -4.2x | --- |
Allogene Therapeutics Inc | 485.5M | -1.3x | --- |
Larimar Therapeutics Inc | 462.6M | -7.5x | --- |
Company Information
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Contact Information
- Headquarters
- 240 E. Grand Ave, 2nd FloorSOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-388-5600
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Richard Heyman
- President, Chief Executive Officer, Director
- Jacob Chacko
- Chief Financial Officer
- Dominic Piscitelli
- Chief Medical Officer
- Pratik Multani
- Independent Director
- Mardi Dier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $476.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 67.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.12 |
EPS | $-1.81 |
Book Value | $4.08 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
